T.I.A. revisited: new wine--old bottle.
TIA has been accepted as a concept of transient cerebral ischemia. There is an ever enlarging body of literature sparking controversies considering its natural history, prognosis, outcomes of clinical trials and usefulness of the concept. Much of the controversy is related to the diverse pathophysiology of TIAs, the selection of patients for clinical trials and the associated risk factor in the studied population. The advantages of the concept are a warning of the possibility of future irreversible pathology an opportunity to treat and/or remove risk factors an opportunity to establish a basis for monitoring the patient and making interim decisions concerning intervention. The risks of the concept are: administering a specific therapy to all patients, failure to fully evaluate the patient once the diagnosis is made, tendency to rely on "experts" for guidance. TIA is a useful concept if one recognizes: the pathophysiology is polymorphous and multiplex, the concept is a signal for diligent search for the underlying cause or causes, it is more important to treat the risk factors than to give a specific therapy.
D000925:Anticoagulants / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D002546:Ischemic Attack, Transient / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D012306:Risk
D000925:Anticoagulants